People with Huntington’s disease are more likely to take Austedo (deutetrabenazine) as directed, compared with the similar medication Xenazine (tetrabenazine), according to a new study. The study also found lower discontinuation rates with Austedo, which may suggest that, between these two treatments for chorea, Austedo tends to be better tolerated. “Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington’s Disease: A Retrospective Database Analysis,” was published in Neurology and Therapy. It was sponsored by Teva Pharmaceuticals,…

You must be logged in to read/download the full post.